Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Tenax Therapeutics, Inc. - Common Stock
(NQ:
TENX
)
1.835
+0.035 (+1.94%)
Delayed Quote
Updated: 2:53 PM EST, Nov 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Tenax Therapeutics, Inc. - Common Stock
< Previous
1
2
Next >
Securities Fraud Class Action Lawsuit Pending Against Tenax Therapeutics, Inc.: The Law Offices of Howard G. Smith Highlights Lead Plaintiff Deadline
Today 11:00 EST
From
The Law Offices of Howard G. Smith
Via
Business Wire
Securities Fraud Class Action Filed Against Tenax Therapeutics, Inc.: Glancy Prongay Wolke & Rotter LLP Announces Lead Plaintiff Deadline
Today 11:00 EST
From
Glancy Prongay Wolke & Rotter LLP
Via
Business Wire
SueWallSt Reminds Tenax Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of December 28, 2026 - TENX
Today 10:06 EST
A securities fraud class action puts the Tenax promise-reality gap on the record. Management pointed to a 29-meter Phase 2 walk result, while the lawsuit claims TNX-103 was less effective than...
From
SueWallSt
Via
GlobeNewswire
Securities Fraud Lawsuit Filed Against Tenax Therapeutics, Inc.: The Law Offices of Frank R. Cruz Outlines Lead Plaintiff Deadline
November 02, 2026
From
The Law Offices of Frank R. Cruz
Via
Business Wire
TENX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Tenax Therapeutics Securities Lawsuit - Contact Levi & Korsinsky
November 02, 2026
Important Information Regarding Section 20(a) Individual Liability Claims: Tenax's chief executive and three successive chief financial officers face control person claims over allegedly misleading...
From
Levi & Korsinsky, LLP
Via
GlobeNewswire
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX
November 01, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
TENX Shareholder Alert: December 28, 2026 Lead Plaintiff Deadline in Tenax Therapeutics, Inc. Securities Class Action - Contact Levi & Korsinsky
October 30, 2026
From
Levi & Korsinsky, LLP
Via
ACCESS Newswire
Lost Money on Tenax Therapeutics, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 89.77% Share Price Drop
October 30, 2026
From
Glancy Prongay Wolke & Rotter LLP
Via
Business Wire
Did You Lose Money on Tenax Therapeutics, Inc. Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 89.77% Share Price Decline
October 30, 2026
From
The Law Offices of Howard G. Smith
Via
Business Wire
TENX INVESTOR DEADLINE: Tenax Therapeutics, Inc. Investors with Substantial Losses May Seek to Lead Class Action Lawsuit
October 29, 2026
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX
October 29, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
Lost Money on Tenax Therapeutics, Inc. Shares? The Law Offices of Frank R. Cruz Investigates Potential Securities Fraud After 89.77% Stock Decline
October 29, 2026
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Rosen Law Firm Urges Tenax Therapeutics, Inc. (NASDAQ: TENX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
October 28, 2026
From
Rosen Law Firm
Via
Business Wire
Pomerantz Law Firm Announces the Filing of a Class Action Against Tenax Therapeutics, Inc. and Certain Officers – TENX
October 27, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Investor Alert: Robbins LLP Informs Investors of the Tenax Therapeutics, Inc. Class Action Lawsuit
October 27, 2026
From
Robbins LLP
Via
Business Wire
TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law
August 16, 2026
From
Schall, Brown & Schwartz LLP
Via
Business Wire
TENX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Tenax Therapeutics (TENX)
August 14, 2026
From
Levi & Korsinsky, LLP
Via
Business Wire
Tenax Therapeutics Inc. (NASDAQ: TENX) Near the Top of Equities by Percentage Gain on 2/6
February 06, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Tenax Therapeutics Inc. (NASDAQ: TENX) Announces $15.6M Public Offering
February 10, 2023
Via
Investor Brand Network
Tenax Therapeutics (NASDAQ: TENX) Granted U.S. Patent for IV Levosimendan for Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)
February 02, 2023
Tenax Therapeutics, Inc. (NASDAQ: TENX) is engaged as a specialty pharmaceutical company, which is focused on the research, development and
Via
Spotlight Growth
Topics
Intellectual Property
Tenax Therapeutics Hosting Key Opinion Leader Webinar on TNX-201: A Potential Treatment for Pulmonary Arterial Hypertension (PAH)
May 25, 2022
From
Tenax Therapeutics, Inc.
Via
Business Wire
Tenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension
May 23, 2022
From
Tenax Therapeutics, Inc.
Via
Business Wire
Tenax Therapeutics Announces $8 Million PIPE Offering Priced At-the-Market under Nasdaq Rules
May 18, 2022
From
Tenax Therapeutics, Inc.
Via
Business Wire
Tenax Therapeutics Reports Fiscal Year 2021 Results and Provides Business Update
March 31, 2022
From
Tenax Therapeutics, Inc.
Via
Business Wire
Tenax Therapeutics Announces Two Presentations at Upcoming American College of Cardiology Scientific Sessions
March 30, 2022
From
Tenax Therapeutics, Inc.
Via
Business Wire
NASDAQ:TENX Shareholder Alert: Investigation over Potential Wrongdoing at Tenax Therapeutics, Inc.
↗
February 17, 2022
San Diego, CA -- (SBWIRE) -- 02/17/2022 -- Certain directors of Tenax Therapeutics, Inc. are under investigation concerning potential breaches of fiduciary duties .
Via
SBWire
Investigation for Investors in Tenax Therapeutics, Inc. (NASDAQ:TENX) Shares Announced
↗
December 13, 2021
San Diego, CA -- (SBWIRE) -- 12/13/2021 -- An investigation was announced for investors of Tenax Therapeutics, Inc. (NASDAQ:TENX) shares over potential securities laws violations by Tenax Therapeutics,...
Via
SBWire
NASDAQ:TENX Investor Notice: Investigation over Potential Wrongdoing at Tenax Therapeutics, Inc.
↗
December 01, 2021
San Diego, CA -- (SBWIRE) -- 12/01/2021 -- Certain directors of Tenax Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties.
Via
SBWire
Tenax Therapeutics Reports Third Quarter 2021 Results and Provides Business Update
November 16, 2021
From
Tenax Therapeutics, Inc.
Via
Business Wire
NASDAQ:TENX Investor Notice: Investigation over Possible Securities Laws Violations by Tenax Therapeutics, Inc.
↗
November 09, 2021
San Diego, CA -- (SBWIRE) -- 11/09/2021 -- Tenax Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
